Company intelligence / Profile preview

Adhaere Pharmaceuticals

Skokie, Illinois, United Statespitchbook.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Adhaere Pharmaceuticals developed small molecule agonists targeting CD11b/CD18 for cancer immunotherapy. Its lead candidate LA-1 reached preclinical stage, demonstrating reduced tumor-associated macrophage infiltration and promotion of T-cell anti-tumor immunity in models. The company was acquired in 2018 and did not advance its program to the clinic.[5][7][2][3]

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

leukadherin-1

Pre-clinical

Beyond the preview

Go deeper on Adhaere Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adhaere Pharmaceuticals.

Explore the full profile